<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Mira Pharmaceuticals, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock</link>
<description>Latest news and press releases for Mira Pharmaceuticals, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 23 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/mira-pharmaceuticals-inc-common-stock" rel="self" type="application/rss+xml" />
<item>
<title>MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-reports-mira-55-shows-no-thc-or-rimonabant-associated-cns-side-effects-in-preclinical-studies</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-reports-mira-55-shows-no-thc-or-rimonabant-associated-cns-side-effects-in-preclinical-studies</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Previously shown to deliver morphine-comparable pain relief without opioid-related risks in a validated inflammatory pain model, supporting planned IND</description>
</item>
<item>
<title>MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-completes-phase-1-dosing-of-ketamir-2-8</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-completes-phase-1-dosing-of-ketamir-2-8</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and</description>
</item>
<item>
<title>MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-initiates-final-cohort-123000037</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-initiates-final-cohort-123000037</guid>
<pubDate>Tue, 03 Feb 2026 12:30:00 GMT</pubDate>
<description>Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer Research (AACR)Annual Meeting MIAMI, FLORIDA / ACCESS Newswire / February 3, 2026 /MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" ...</description>
</item>
<item>
<title>Specialist Direct's ‘Mira’ Partners with dacadoo to Transform Recovery Management and Wellness Outcomes</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/specialist-directs-mira-partners-with-dacadoo-to-transform-recovery-management-and-wellness-outcomes</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/specialist-directs-mira-partners-with-dacadoo-to-transform-recovery-management-and-wellness-outcomes</guid>
<pubDate>Thu, 30 Oct 2025 00:00:00 GMT</pubDate>
<description>Strategic integration of advanced health engagement technology to enhance recovery journeys and promote healthier lifestylesZurich, Switzerland, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Specialist Direct, a digital health solutions subsidiary company of Swisstec, announced a global strategic partnership with dacadoo, a digital health engagement company. Mira, Specialist Direct’s case management platform, is focused on guiding patients through injury and illness recovery. dacadoo’s Digital Health Engage</description>
</item>
<item>
<title>MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-initiates-multiple-ascending-113000210</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-initiates-multiple-ascending-113000210</guid>
<pubDate>Fri, 24 Oct 2025 11:30:00 GMT</pubDate>
<description>Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration MIAMI, FLORIDA / ACCESS Newswire / October 24, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ...</description>
</item>
<item>
<title>MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-announces-oral-mira-113000209</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-announces-oral-mira-113000209</guid>
<pubDate>Thu, 16 Oct 2025 11:30:00 GMT</pubDate>
<description>Findings show oral Mira-55 fully normalized pain and significantly reduced inflammation, supporting IND plans and reinforcing MIRA's position in a $70 billion non-opioid pain market. MIAMI, FLORIDA / ACCESS Newswire / October 16, 2025 /MIRA Pharmaceuticals, ...</description>
</item>
<item>
<title>MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-closes-acquisition-skny-113000661</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-closes-acquisition-skny-113000661</guid>
<pubDate>Tue, 30 Sep 2025 11:30:00 GMT</pubDate>
<description>Closing adds $5 million in marketable securities, strengthens financial position, and complements MIRA's advancing programs including Ketamir-2 and MIRA-55 MIAMI, FLORIDA / ACCESS Newswire / September 30, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ...</description>
</item>
<item>
<title>MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-announces-favorable-topline-120000435</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-announces-favorable-topline-120000435</guid>
<pubDate>Mon, 22 Sep 2025 12:00:00 GMT</pubDate>
<description>Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed. The drug showed rapid and predictable absorption, a favorable ...</description>
</item>
<item>
<title>MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-reports-positive-ptsd-113000811</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-reports-positive-ptsd-113000811</guid>
<pubDate>Tue, 16 Sep 2025 11:30:00 GMT</pubDate>
<description>MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such as PTSD MIAMI, FLORIDA / ACCESS Newswire / September 16, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), ...</description>
</item>
<item>
<title>MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-shareholders-approve-acquisition-113000994</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-shareholders-approve-acquisition-113000994</guid>
<pubDate>Fri, 12 Sep 2025 11:30:00 GMT</pubDate>
<description>SKNY transaction strengthens MIRA pipeline with SKNY-1, a differentiated oral candidate that has demonstrated up to 30% weight loss and nicotine craving reversal in preclinical studies. MIAMI, FL / ACCESS Newswire / September 12, 2025 / MIRA Pharmaceuticals, ...</description>
</item>
<item>
<title>Mira Introduces Ultra4™, the First At-Home Hormone Monitor with Lab-Quality 4-in-1 Testing</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-introduces-ultra4tm-the-first-at-home-hormone-monitor-with-lab-quality-4-in-1-testing</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-introduces-ultra4tm-the-first-at-home-hormone-monitor-with-lab-quality-4-in-1-testing</guid>
<pubDate>Mon, 25 Aug 2025 17:00:00 GMT</pubDate>
<description>Mira, a leading hormonal health company, launches Ultra4™, the first at-home hormone monitor to deliver lab-quality insights into four key hormones (FSH, LH, E3G, and PdG) with just one wand and a 16-minute test. For the first time, people can see their full cycle story — from ovulation strength to hormonal balance — with the same precision once only available in clinics.</description>
</item>
<item>
<title>MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-announces-completion-phase-123000959</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-announces-completion-phase-123000959</guid>
<pubDate>Tue, 19 Aug 2025 12:30:00 GMT</pubDate>
<description>Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage ...</description>
</item>
<item>
<title>MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-second-ketamir-2-123000052</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-second-ketamir-2-123000052</guid>
<pubDate>Tue, 12 Aug 2025 12:30:00 GMT</pubDate>
<description>Manuscript accepted for publication in Frontiers in Pharmacology, "Oral Administration of Ketamir-2, a Novel Ketamine Analog, Attenuates Neuropathic Pain in Rodent Models via Selective NMDA Antagonism" details Ketamir-2's superior performance in two ...</description>
</item>
<item>
<title>MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-reports-topical-ketamir-113000000</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-reports-topical-ketamir-113000000</guid>
<pubDate>Wed, 30 Jul 2025 11:30:00 GMT</pubDate>
<description>Topical Ketamir-2 significantly reduced both acute and inflammatory pain behaviors in animals, demonstrating rapid onset, durable effect, and comparable efficacy to injected morphine across both pain phases MIAMI, FLORIDA / ACCESS Newswire / July ...</description>
</item>
<item>
<title>MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-announces-fda-clearance-113000554</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-announces-fda-clearance-113000554</guid>
<pubDate>Tue, 29 Jul 2025 11:30:00 GMT</pubDate>
<description>Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion as the Company prepares to launch U.S. Phase 2a by year-end MIAMI, FLORIDA / ACCESS Newswire / July 29, 2025 / MIRA Pharmaceuticals, ...</description>
</item>
<item>
<title>MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-reports-clear-reversal-anxiety-120000587</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-reports-clear-reversal-anxiety-120000587</guid>
<pubDate>Fri, 11 Jul 2025 12:00:00 GMT</pubDate>
<description>SKNY-1 was previously shown to achieve up to 30% weight loss, reverse nicotine craving, and preserve muscle mass in an animal model-and is designed to avoid the CNS side effects that halted earlier CB1-targeting drugs MIAMI, FL / ACCESS Newswire / ...</description>
</item>
<item>
<title>MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-reports-potent-inflammatory-pain-120000241</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-reports-potent-inflammatory-pain-120000241</guid>
<pubDate>Thu, 03 Jul 2025 12:00:00 GMT</pubDate>
<description>With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage ...</description>
</item>
<item>
<title>MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-reports-30-weight-loss-120000168</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-reports-30-weight-loss-120000168</guid>
<pubDate>Mon, 30 Jun 2025 12:00:00 GMT</pubDate>
<description>Oral therapy designed to minimize CNS side effects shows dual activity in weight loss and smoking cessation models without muscle loss MIAMI, FLORIDA / ACCESS Newswire / June 30, 2025 / MIRA (NASDAQ:MIRA) today announced new animal study results from ...</description>
</item>
<item>
<title>MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-announces-data-underscoring-120000697</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-announces-data-underscoring-120000697</guid>
<pubDate>Wed, 25 Jun 2025 12:00:00 GMT</pubDate>
<description>MIAMI, FL / ACCESS Newswire / June 25, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, ...</description>
</item>
<item>
<title>MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology</title>
<link>https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-lead-drug-candidate-123000930</link>
<guid isPermaLink="true">https://6ix.com/company/mira-pharmaceuticals-inc-common-stock/news/mira-pharmaceuticals-lead-drug-candidate-123000930</guid>
<pubDate>Wed, 18 Jun 2025 12:30:00 GMT</pubDate>
<description>MIAMI, FL / ACCESS Newswire / June 18, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today ...</description>
</item>
</channel>
</rss>